These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30870475)

  • 1. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home.
    Lasser KE; Heinz A; Battisti L; Akoumianakis A; Truong V; Tsui J; Ruiz G; Samet JH
    Ann Fam Med; 2017 May; 15(3):258-261. PubMed ID: 28483892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
    Zeta LM
    Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
    Malouin RA; Mckernan L; Forsberg A; Cheng D; Drake J; McLaughlin K; Trujillo M
    Matern Child Health J; 2018 Sep; 22(9):1240-1246. PubMed ID: 29948762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
    Health Resources and Services Administration, Department of Health and Human Services (HHS)
    Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The unintended consequences of the 340B safety-net drug discount program.
    Thomas S; Schulman K
    Health Serv Res; 2020 Apr; 55(2):153-156. PubMed ID: 32114714
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
    Conti RM; Bach PB
    Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ensuring access to prescription medications in the post-ACA healthcare access landscape: the essential role of FQHCs in the safety net for the underinsured.
    Shi L; Wharton MK; Monnette A
    Am J Manag Care; 2018 Mar; 24(5 Suppl):S67-S73. PubMed ID: 29620813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
    Clark BL; Hou J; Chou CH; Huang ES; Conti R
    Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
    Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
    JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
    Li Y; Xu S
    JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
    Mulligan K; Romley JA; Myerson R
    BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of the 340B Drug Pricing Program.
    Desai S; McWilliams JM
    N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.
    Levengood TW; Conti RM; Cahill S; Cole MB
    Milbank Q; 2024 Jun; 102(2):429-462. PubMed ID: 38282421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 340B Participation and Safety Net Engagement Among Federally Qualified Health Centers.
    Watts E; McGlave C; Quinones N; Bruno JP; Nikpay S
    JAMA Health Forum; 2024 Oct; 5(10):e243360. PubMed ID: 39365605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the 340B Drug Discount Program in Recent Cancer Care Trends.
    Kantarjian HM; Chapman R
    J Oncol Pract; 2015 Jul; 11(4):303-7. PubMed ID: 26036268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
    Lee CH; Chang J; McCombs J
    J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.